vs
Side-by-side financial comparison of AdvanSix Inc. (ASIX) and iRhythm Holdings, Inc. (IRTC). Click either name above to swap in a different company.
AdvanSix Inc. is the larger business by last-quarter revenue ($359.9M vs $208.9M, roughly 1.7× iRhythm Holdings, Inc.). iRhythm Holdings, Inc. runs the higher net margin — 2.7% vs -0.8%, a 3.4% gap on every dollar of revenue. On growth, iRhythm Holdings, Inc. posted the faster year-over-year revenue change (27.1% vs 9.4%). AdvanSix Inc. produced more free cash flow last quarter ($36.1M vs $14.5M). Over the past eight quarters, iRhythm Holdings, Inc.'s revenue compounded faster (25.8% CAGR vs 3.4%).
AdvanSix Inc. is an American chemical company that produces nylon 6 and related chemicals such as caprolactam and ammonium sulfate fertilizers. It operated as Honeywell's Resins and Chemicals division until 2016, when it was spun off as a separate company. The unit accounted for 3 percent of Honeywell's sales at the time. For 2019, revenue is estimated at $1.4 billion. The company traces its lineage to the H. W. Jayne Company, established 1884 in Frankford, Pennsylvania.
iRhythm Holdings is a digital healthcare company focused on cardiac care, developing and commercializing wearable ambulatory heart monitoring devices paired with AI-powered analytical tools. It primarily serves healthcare providers and patients across the United States, helping to detect undiagnosed arrhythmias such as atrial fibrillation through convenient long-term heart rhythm tracking that delivers actionable clinical insights.
ASIX vs IRTC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $359.9M | $208.9M |
| Net Profit | $-2.8M | $5.6M |
| Gross Margin | 7.6% | 70.9% |
| Operating Margin | -0.7% | 1.1% |
| Net Margin | -0.8% | 2.7% |
| Revenue YoY | 9.4% | 27.1% |
| Net Profit YoY | -892.9% | 518.5% |
| EPS (diluted) | $-0.11 | $0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $359.9M | $208.9M | ||
| Q3 25 | $374.5M | $192.9M | ||
| Q2 25 | $410.0M | $186.7M | ||
| Q1 25 | $377.8M | $158.7M | ||
| Q4 24 | $329.1M | $164.3M | ||
| Q3 24 | $398.2M | $147.5M | ||
| Q2 24 | $453.5M | $148.0M | ||
| Q1 24 | $336.8M | $131.9M |
| Q4 25 | $-2.8M | $5.6M | ||
| Q3 25 | $-2.6M | $-5.2M | ||
| Q2 25 | $31.4M | $-14.2M | ||
| Q1 25 | $23.3M | $-30.7M | ||
| Q4 24 | $352.0K | $-1.3M | ||
| Q3 24 | $22.3M | $-46.2M | ||
| Q2 24 | $38.9M | $-20.1M | ||
| Q1 24 | $-17.4M | $-45.7M |
| Q4 25 | 7.6% | 70.9% | ||
| Q3 25 | 6.8% | 71.1% | ||
| Q2 25 | 14.3% | 71.2% | ||
| Q1 25 | 14.2% | 68.8% | ||
| Q4 24 | 3.4% | 70.0% | ||
| Q3 24 | 14.4% | 68.8% | ||
| Q2 24 | 17.9% | 69.9% | ||
| Q1 24 | 0.9% | 66.3% |
| Q4 25 | -0.7% | 1.1% | ||
| Q3 25 | -0.9% | -4.4% | ||
| Q2 25 | 7.7% | -10.0% | ||
| Q1 25 | 7.7% | -20.5% | ||
| Q4 24 | -3.9% | -2.5% | ||
| Q3 24 | 7.5% | -34.1% | ||
| Q2 24 | 11.5% | -15.5% | ||
| Q1 24 | -7.0% | -28.9% |
| Q4 25 | -0.8% | 2.7% | ||
| Q3 25 | -0.7% | -2.7% | ||
| Q2 25 | 7.7% | -7.6% | ||
| Q1 25 | 6.2% | -19.3% | ||
| Q4 24 | 0.1% | -0.8% | ||
| Q3 24 | 5.6% | -31.3% | ||
| Q2 24 | 8.6% | -13.6% | ||
| Q1 24 | -5.2% | -34.6% |
| Q4 25 | $-0.11 | $0.18 | ||
| Q3 25 | $-0.10 | $-0.16 | ||
| Q2 25 | $1.15 | $-0.44 | ||
| Q1 25 | $0.86 | $-0.97 | ||
| Q4 24 | $0.02 | $-0.03 | ||
| Q3 24 | $0.82 | $-1.48 | ||
| Q2 24 | $1.43 | $-0.65 | ||
| Q1 24 | $-0.65 | $-1.47 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $19.8M | $583.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $815.2M | $152.7M |
| Total Assets | $1.7B | $1.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $19.8M | $583.8M | ||
| Q3 25 | $23.7M | $565.2M | ||
| Q2 25 | $18.4M | $545.5M | ||
| Q1 25 | $8.3M | $520.6M | ||
| Q4 24 | $19.6M | $535.6M | ||
| Q3 24 | $17.3M | $522.0M | ||
| Q2 24 | $12.1M | $561.5M | ||
| Q1 24 | $20.6M | $569.1M |
| Q4 25 | $815.2M | $152.7M | ||
| Q3 25 | $818.2M | $121.9M | ||
| Q2 25 | $823.7M | $103.7M | ||
| Q1 25 | $794.4M | $86.7M | ||
| Q4 24 | $774.6M | $90.9M | ||
| Q3 24 | $766.4M | $71.8M | ||
| Q2 24 | $746.6M | $99.2M | ||
| Q1 24 | $713.2M | $90.3M |
| Q4 25 | $1.7B | $1.0B | ||
| Q3 25 | $1.7B | $995.2M | ||
| Q2 25 | $1.6B | $964.0M | ||
| Q1 25 | $1.6B | $926.1M | ||
| Q4 24 | $1.6B | $931.4M | ||
| Q3 24 | $1.5B | $909.7M | ||
| Q2 24 | $1.5B | $919.2M | ||
| Q1 24 | $1.5B | $909.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $63.7M | $26.2M |
| Free Cash FlowOCF − Capex | $36.1M | $14.5M |
| FCF MarginFCF / Revenue | 10.0% | 6.9% |
| Capex IntensityCapex / Revenue | 7.7% | 5.6% |
| Cash ConversionOCF / Net Profit | — | 4.70× |
| TTM Free Cash FlowTrailing 4 quarters | $6.4M | $34.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.7M | $26.2M | ||
| Q3 25 | $26.6M | $34.9M | ||
| Q2 25 | $21.1M | $27.7M | ||
| Q1 25 | $11.4M | $-7.9M | ||
| Q4 24 | $64.2M | $19.2M | ||
| Q3 24 | $57.3M | $24.3M | ||
| Q2 24 | $50.2M | $11.8M | ||
| Q1 24 | $-36.2M | $-52.0M |
| Q4 25 | $36.1M | $14.5M | ||
| Q3 25 | $66.0K | $20.1M | ||
| Q2 25 | $-7.2M | $17.3M | ||
| Q1 25 | $-22.6M | $-17.3M | ||
| Q4 24 | $29.8M | $12.4M | ||
| Q3 24 | $26.8M | $15.5M | ||
| Q2 24 | $16.7M | $3.4M | ||
| Q1 24 | $-71.6M | $-61.8M |
| Q4 25 | 10.0% | 6.9% | ||
| Q3 25 | 0.0% | 10.4% | ||
| Q2 25 | -1.7% | 9.3% | ||
| Q1 25 | -6.0% | -10.9% | ||
| Q4 24 | 9.1% | 7.5% | ||
| Q3 24 | 6.7% | 10.5% | ||
| Q2 24 | 3.7% | 2.3% | ||
| Q1 24 | -21.3% | -46.8% |
| Q4 25 | 7.7% | 5.6% | ||
| Q3 25 | 7.1% | 7.7% | ||
| Q2 25 | 6.9% | 5.6% | ||
| Q1 25 | 9.0% | 5.9% | ||
| Q4 24 | 10.4% | 4.2% | ||
| Q3 24 | 7.7% | 6.0% | ||
| Q2 24 | 7.4% | 5.7% | ||
| Q1 24 | 10.5% | 7.4% |
| Q4 25 | — | 4.70× | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 0.49× | — | ||
| Q4 24 | 182.29× | — | ||
| Q3 24 | 2.57× | — | ||
| Q2 24 | 1.29× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
IRTC
| Commercial Payors | $111.7M | 53% |
| Centers For Medicare And Medicaid | $49.2M | 24% |
| Healthcare Institutions | $34.3M | 16% |
| Non Contracted Third Party Payors | $13.7M | 7% |
